B
cell development initiates during embryogenesis (1, 2) . However, rather than being a linear process in which all types of B cells are generated, at least two distinct waves of fetal B lymphopoiesis have been defined (3) . During the first, B-1 progenitors are generated. These cells ultimately mature into innate-like B-1a and B-1b cells that provide defense against pathogens that include encapsulated bacteria (4, 5) . Subsequently, B-2 B cell progenitors arise, and they are the predominant B cell progenitor population present in postnatal bone marrow (6) . Most B lymphocytes in peripheral immune tissues are B-2 B cells, which are involved in adaptive immune responses (7) .
In addition to differences in the kinetics with which they appear during embryogenesis, B-1 and B-2 progenitors can be distinguished by their cytokine responsiveness. For example, B-1 progenitors proliferate more vigorously to IL-7 than do B-2 progenitors (8) . Additionally, B-1, but not B-2, progenitors can be distinguished based on their ability to respond to thymic stromal lymphopoietin (TSLP) (6, 9) . It was initially proposed that TSLP had no effect on adult pro-B cells and its actions were limited to B cell progenitors in fetal tissues (10) . However, we subsequently demonstrated that B cell lineage defined TSLP responsiveness. Thus, B-1 progenitors from fetal liver and young adult bone marrow responded to TSLP whereas B-2 progenitors, regardless of whether they were isolated from fetal or adult tissues, could not do so (6) .
Taken together with the differences in the kinetics with which they arise, these observations demonstrate that B-1 and B-2 progenitors exhibit distinct properties.
B-acute lymphoblastic leukemia (B-ALL) is the most common pediatric malignancy (11, 12) . Although up to 80% of B-ALL patients respond well to treatment and survive long-term, the remaining 20% often have a poor prognosis (13) . Various chromosomal translocations, such as ETV6-RUNX1 (TEL-AML1), MLL-AF4, and BCR-ABL, frequently underlie B-ALL and have been used to stratify patients into risk groups predictive of survival or therapeutic response (11, 14) . For example, children with the BCR-ABL translocation, which encodes the Philadelphia chromosome, are classified as high risk based on elevated leukocyte counts at diagnosis, CNS involvement, and poor response to treatment (15) (16) (17) (18) . Many of these chromosomal translocations occur in the human fetus (19, 20) . Interestingly, this is the time that murine B-1 progenitor numbers peak (3) . If human B-1 progenitor numbers are at their maximum at this time as well, then some infant and pediatric B-ALL cases could be B-1 malignancies. However, whether B-ALL can arise in B-1 progenitors has not been tested.
We now report that B-1 progenitors can be ALL cells of origin and demonstrate that BCR-ABL-transduced B-1 progenitors initiate disease more rapidly than do oncogene-expressing B-2 progenitors. We further propose, based on in vitro modeling of ALL, that the high proliferative potential and relative resistance to oncogene-induced apoptosis of B-1 progenitors underlie the accelerated kinetics with which they initiate leukemia. Taken together, these results further define differences between the B-1 and B-2 lineages and provide a novel developmental perspective on the origins of pediatric ALL.
Materials and Methods

Mice
Swiss Webster (SW), CB17.SCID, and RAG-2/SJL (RAG, B6.SJL(129S6)-Ptprca/BoCrTac-Rag2 tm1 ) mice were obtained from Taconic Farms (Germantown, NY). TSLP receptor-deficient (CRLF2 Production of retroviral stocks pMSCV40 retroviral vectors containing either a 59 LTR-driven p210 BCR-ABL internal ribosome entry site-enhanced GFP (EGFP; BCR-ABL/GFP) or a 59 LTR-driven internal ribosome entry site EGFP (GFP only) were used to generate high-titer helper-free retrovirus supernatants following transient cotransfection of 293T cells. 293T cells were grown in 10-cm 2 tissue culture treated plates (Becton Dickinson) precoated with poly-L-lysine (SigmaAldrich) in IMDM (Mediatech, Manassas, VA) supplemented with 10% heat-inactivated FCS (HyClone, Logan, UT), 1 mM L-glutamine, 100 U/ml streptomycin, and 100 mg/ml penicillin (complete IMDM; all from Life Technologies, St. Louis, MO). 293T transfections were performed by coprecipitating 15 mg retroviral vector with 15 mg ecotropic packaging vector using the CalPhos mammalian transfection kit (BD Biosciences, San Jose, CA). Medium was replaced every 12 h for 3 d with complete IMDM. Viral stocks were prepared by pooling supernatants collected at 36 and 48 h after transfection. Viral titers were determined following infection of 3T3 cells with serial dilutions of the pooled virus supernatant and found to range between 2 3 10 6 and 7 3 10 6 virus particles/ml.
Cell culture and transductions
B-1 and B-2 progenitors were plated in 3 ml RPMI 1640 medium supplemented with 10% heat-inactivated FCS, 1 mM L-glutamine, 100 U/ml streptomycin, 100 mg/ml penicillin, 50 mM 2-ME, 50 mg/ml gentamicin, stem cell factor (20 ng/ml), IL-3 (20 ng/ml), Flt-3L (10 ng/ml), IL-7 (30 ng/ml; all from Life Technologies), and 4 mg/ml polybrene. Transwell inserts (0.4 mm) preseeded with confluent layers of the S17 stromal cell line were inserted into each well. GFP only or BCR-ABL/GFP retrovirus supernatants were added to the bottom wells containing the purified progenitor populations at t = 0, 4, 16, and 20 h of culture. After a total of 24 h in culture at 37˚C, 5% CO 2 /air humidified incubator, the cells were harvested and viable cell counts were determined by eosin dye exclusion.
Transplantation
Transduced SW cells were injected i.v. into SCID mice whereas RAG mice were used as recipients of transduced cells from B6, CRLF2
2/2
, and IL7Ra 2/2 donors. The number of transduced cells injected is indicated in the figure legends. SCID and RAG recipients were conditioned with 300 or 550 rad, respectively, from a 137 Cs irradiator (120 rad/min; Mark I-68A; J.L. Shepherd and Associates, San Fernando, CA) 12-24 h prior to injection of cells. Recipients were sacrificed when they became moribund. Their tissues were tested for the presence of donor-derived B-ALL tumor cells through coexpression of GFP and B lineage cell surface Ags as described above.
Quantitative PCR
Flash-frozen aliquots of purified cells were processed for gene expression by quantitative PCR. Total RNA was extracted with the RNeasy Plus micro kit and used to synthetize cDNA with the RT 2 First Strand kit (both from Qiagen, Valencia, CA) as per the manufacturer's instructions. Reactions were run in 25-ml volumes with SYBR Green quantitative PCR master mix (Bio-Rad) as recommended by the manufacturer. Amplification efficiencies were routinely found to be between 95 and 105%, and all reactions were run in duplicate. RT 2 primer sets for p19 Arf, whose sequences were 59-GCTCTGGCTTTCGTGAACATG-39 (forward) and 59-TCGAATCTG-CACCGTAGTTGAG-39 (reverse), and Gapdh (catalog no. PPM02946A) were purchased from SABiosciences. Presence of single PCR products was confirmed by melt curve analysis. Data were analyzed with Bio-Rad IQ5 software using the Pfaffl method with Gapdh as a reference gene.
Gene expression in tumor cells harvested from mice was analyzed using a custom RT 2 PCR array designed by Qiagen (Germantown, MD; no. CAPM11051) as per the manufacturer's instructions. Expression of the following genes was examined: Jak1, Jak2, Stat1, Stat3, Stat5a, Stat5b, Akt1, Mcl1, and Grb2. The 2 2DCt values for the custom array were calculated using the Pfaffl method with the means of the Ct values for Actb and Hsp90ab1 housekeeping genes as reference. Quality control for the custom array quantitative PCR reactions and gene expression analyses were performed on the Qiagen PCR array data analysis Web portal (http:// pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php?target= upload).
Statistical analysis
Data are expressed as means 6 SEM. Statistical significance for the differences between groups was determined by a two-tailed, unpaired Student t test (a = 0.05). The log-rank (Mantel-Cox) test was used to assess differences in the rate of ALL development between different groups of mice. + phenotypes (7), respectively (Supplemental Fig. 1 ), and they have been shown to differentiate into mature B-1 and B-2 cells following transplantation into immunodeficient recipients (6) (Supplemental Fig. 2 ). Because progenitors for these two B cell lineages arise in overlapping waves of development (3, 6), we were able to isolate both populations from the same bone marrow samples from SW mice, although in initial experiments we also purified B-1 progenitors from day 15 gestation fetal liver. Purified populations were transduced for 24 h in vitro with retroviral vectors containing BCR-ABL/GFP or GFP only. Cells were then harvested, washed, and transplanted i.v. into immunodeficient recipients. BCR-ABL was used in this study because we previously demonstrated its potential to transform B-2 pro-B cells (22), thus providing a reproducible model system to examine the leukemogenic potential of B lineage progenitors.
Results
B-1 progenitors initiate a rapidly developing leukemia
Several mice that received BCR-ABL/GFP-transduced B-1 progenitors derived from fetal liver or young adult bone marrow became moribund as early as 18 d later, and by 40 d all recipients had to be sacrificed due to severe wasting symptoms. BCR-ABL/GFP-transduced B-1 progenitors from fetal liver or young adult bone marrow initiated B-ALL with similar kinetics (Fig. 1A) . In contrast, recipients of BCR-ABL/GFP-transduced B-2 progenitors first showed signs of disease at around day 30 after transplantation, and many mice survived past 60 d (Fig. 1A) .
The tumor burden in recipient mice, assessed by quantifying the number of GFP + cells, was nearly 2-fold higher in the spleen of mice that received transformed B-1 compared with B-2 progenitors (Fig. 1B) . Regardless of whether they were derived from B-1 or B-2 progenitors, .95% of the tumor cells in the mice were CD19 + CD45R (B220) + surface IgM (sIgM) -pro/pre-B cells (Fig. 1C,  Supplemental Fig. 3) .
B-1 and B-2 progenitors are transduced with comparable efficiency
The above results show that recipients of 3 3 10 4 B-1 progenitors developed disease more rapidly than did recipients of a comparable number of BCR-ABL-transduced B-2 progenitors. However, it was critical to determine whether the mice received a similar number of transduced cells. Although the BCR-ABL-containing retroviral construct contained a GFP reporter gene, its expression was inefficient at 24 h following transduction when cells were injected into animals. We thus cultured cell aliquots for 64 h and then measured GFP expression in the transduced B-1 and B-2 progenitors. As shown in Fig. 2A , there was no significant difference in their level of GFP expression, making it unlikely that differences in the number of transduced cells injected accounted for the more rapid development of B-1 progenitor ALL. This was further confirmed by comparing the kinetics of B-ALL development in recipients following injection of twice as many BCR-ABL/ GFP-transduced B-2 than B-1 progenitors. As shown in Fig. 2B , recipients of 5 3 10 3 BCR-ABL/GFP-transduced B-1 progenitors still developed disease more rapidly than did recipients of 1 3 10 4 BCR-ABL/GFP-transduced B-2 cells. This result indicates that, within the range of cell doses tested, the latency in B-ALL emergence was linked to the lineage and not the number of transduced cells transplanted.
B-1 progenitors from CRLF2
2/2 and IL-7Ra 2/2 mice can initiate B-ALL B-1 progenitors proliferate vigorously in response to IL-7 (Table I) and are distinguished from B-2 progenitors by their TSLP responsiveness (6). To determine whether TSLP and IL-7 responsiveness were necessary for the development of B-1 progenitor ALL, we tested whether B-1 progenitors isolated from CRLF2 2/2 mice, which do not express the TSLP receptor, and IL-7Ra
mice can initiate disease following transduction with BCR-ABL. B-1 progenitors were easily detected in CRLF2 2/2 mice, indicating that signaling through the TSLP receptor is not required for their formation and/or maintenance (Fig. 3A) . B-1 progenitors are also present in IL-7Ra 2/2 mice, albeit in reduced numbers, indicating that IL-7 signaling is required for their emergence in normal numbers (Fig. 3B ). Because CRLF2 2/2 and IL-7Ra 2/2 mice are on a B6 background, we first established that B-ALL also developed in that strain. Recipients of 1 3 10 4 BCR-ABL-transduced B6 B-1 progenitors efficiently initiated leukemia, and all mice had succumbed by day 45 thereafter (Fig. 3C) . In contrast, the kinetics with which disease initiated in recipients of BCR-ABL-transduced B6 B-2 progenitors were delayed. In fact, some mice had not developed leuke- (Fig. 3D) and a higher number of transduced B-2 progenitors was injected into recipients (Fig. 3C) .
We then assessed whether BCR-ABL-transduced CRLF2 2/2 and IL-7Ra 2/2 B-1 progenitors could initiate disease and found that they could do so. In this case, the kinetics with which B6, CRLF2
2/2
, and IL-7Ra 2/2 B-1 progenitors developed disease were similar (Fig. 3C) .
As with SW progenitors, recipients of the BCR-ABL-transduced B6, CRLF2 2/2 , and IL-7Ra 2/2 B-1 progenitors developed tumors in their bone marrow and spleen (data not shown) that were primarily CD45R (B220) + sIgM - (Fig. 3E) . Taken together, these data indicate that the initiation and progression of B-1 progenitor B-ALL is not dependent on signaling through the TSLP or IL-7 receptor. Because deletion of IL-7Ra abrogates both IL-7 and TSLP signaling, these data further indicate that B-1 progenitors can initiate B-ALL even when both pathways are simultaneously disabled.
B-1 and B-2 progenitor tumors exhibit similar levels of proliferation
Even though the latency periods with which B-1 and B-2 progenitor ALL developed were distinct, once mice exhibited disease symptoms, their clinical course was indistinguishable and they rapidly succumbed within a week (data not shown). These observations suggested that the properties of established ALL tumor cells were similar, regardless of their B-1 or B-2 progenitor origin. We initially compared the expression of selected genes, which included Jak1, Jak2, Stat1, Stat3, Stat5a, Stat5b, Akt1, Mcl1, and Grb2, in the BCR-ABL signaling pathway in tumor cells. Mice received BCR-ABL-transduced B-1 and/or B-2 progenitors from B6, CRLF2 2/2 , and IL-7Ra 2/2 donors, and GFP + tumor cells were harvested from animals when they became moribund. These genes were generally expressed at similar levels in the tumors regardless of lineage or strain of origin (Fig. 4A) .
Activation of JAK/STAT signaling is commonly observed in BCR-ABL-transformed cells (23-25), so we next compared the activation of this pathway in B-1 and B-2 progenitor tumors. We isolated BCR-ABL-expressing (i.e., GFP + ) tumor cells from the spleen of mice that had received an injection of transduced B-1 and B-2 progenitors and examined Stat5 levels by phospho-flow analysis. As shown in Fig. 4B , levels were indistinguishable between the GFP-expressing tumor cells isolated from wild-type, CRLF2
2/2
, and IL-7Ra 2/2 mice.
We also observed that the various tumor cells exhibited similar levels of proliferation as measured by Ki-67 (Fig. 4C) .
The initial response of B-1 and B-2 progenitors to oncogene expression is distinct
The above results indicate that established B-1 and B-2 progenitor tumors are similar in terms of phenotype, gene expression, Stat5 activation, and proliferation. These observations suggest that events leading up to tumor formation, rather than the properties of ALL tumor cells, underlie the rapid development of B-1 progenitor ALL.
To test this hypothesis, we assessed how the two progenitor populations responded to oncogene expression by transducing them with BCR-ABL, placing them in culture under B lymphopoietic conditions, and comparing their growth and survival 64 h later. The number of cells present in cultures seeded with BCR-ABL/ GFP-or GFP only-transduced B-1 progenitors was higher than in those initiated with similarly transduced B-2 progenitors (Fig. 5A) . This result likely reflects the higher proliferative potential of B-1 progenitors compared with B-2 progenitors, irrespective of transduction (Table I) . Additionally, the distinct ) are undergoing cell death (27) . We found that very few B-1 and B-2 progenitors bind annexin V, and those that do are annexin V +/high (Supplemental Fig. 4 ). Taken together, these observations indicate that annexin V +/high binding can be used as a marker for apoptosis in these B cell progenitors.
Whereas transduction with the GFP-only vector induced cell death in both progenitor populations, the frequency and number of GFP + annexin V +/high and/or PI + apoptotic cells were highest in cultures established with BCR-ABL-transduced B-2 progenitors (Fig. 5B, 5C ). That cell death occurred following BCR-ABL expression is not unexpected, because this event is known to trigger an apoptotic response in B cell progenitors (28) . However, the higher number of apoptotic cells in the cultures initiated with BCR-ABL-transduced B-2 progenitors suggests that they are more sensitive to oncogene expression. Cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FCS, 1 mM L-glutamine, 100 U/ml streptomycin, 100 mg/ml penicillin, 50 mM 2-ME, 50 mg/ml gentamicin, stem cell factor (20 ng/ml), IL-3 (20 ng/ml), and Flt-3L (10 ng/ml) with or without IL-7 (30 ng/ml) for 7 d at 37˚C in a 5% CO 2 /air-humidified incubator, at which time the numbers of live cells were counted by eosin dye exclusion. The Journal of Immunology
To define a genetic basis for the latter hypothesis, we examined expression of the p19
Arf tumor suppressor gene in nontransduced, GFP only-transduced, and BCR-ABL/GFP-transduced B-1 and B-2 progenitors. The expression of p19
Arf in B cell progenitors is known to trigger apoptosis through induction of p53 (28) . p19
Arf was expressed in unmanipulated B-1 progenitors and its levels did not significantly change following transduction with GFP or BCR-ABL. In contrast, p19
Arf was not detected in unmanipulated B-2 progenitors, but expression was induced following BCR-ABL expression. This induction was not due to the transduction process alone, as p19
Arf levels were higher in the oncogene-transduced compared with the GFP only-transduced cells (Fig. 5D ). These differences in the response of B-1 and B-2 progenitors to BCR-ABL expression are particularly well illustrated when the relative level at which p19
Arf is induced is compared (Fig. 5E ).
Discussion
The data in this study demonstrate that B-1 progenitors can be B-ALL cells of origin and that, compared with B-2 progenitors, they initiate an aggressive form of the disease characterized by rapid onset and high tumor burden. These results provide a new conceptual framework for viewing the origins of infant and childhood B-ALL. Whereas most focus has been placed on the specific chromosomal translocation and/or secondary mutations as key events in leukemia initiation and progression, our data indicate that B cell lineage may also be a significant factor. Specifically, our results indicate that intrinsic differences between B-1 and B-2 progenitors exist and influence their response to BCR-ABL expression. These results reinforce the concept that the cellular landscape in which oncogene expression occurs is an important determinant for ALL development. In this regard, we recently demonstrated that the potential of BCR-ABL to transform young and old pro-B cells was distinctly different because of differences in patterns of gene expression between these progenitors (29) . A key finding of this study was that the kinetics with which B-1 and B-2 progenitor ALL developed were significantly different. This result was not related to the number of transduced cells introduced into the recipients, because B-1 and B-2 progenitors were transduced with similar efficiency. We considered the possibility that TSLP responsiveness was responsible for the aggressive nature of B-1 progenitor ALL, because B-1, but not B-2, progenitors are TSLP responsive (6, 9) and CRLF2 expression has been associated with poor ALL outcome (17, 30, 31) . Our data showing that CRLF2-deficient B-1 progenitors still initiated rapid ALL suggest that TSLP responsiveness was not critical for the initiation of B-1 progenitor ALL. This was further confirmed by the observation that abrogation of IL-7Ra expression, which results in disruption of TSLP and IL-7 signaling, did not affect the initiation of B-1 progenitor ALL.
Examination of established B-1 and B-2 progenitor tumors did not provide insights into why B-1 progenitor ALL developed so rapidly. Tumor cells, regardless of whether they were derived from wild-type, CRLF2 Unmanipulated B-1 progenitors appear to tolerate low levels of p19 Arf , and BCR-ABL expression did not induce it to higher levels. In contrast, unmanipulated B-2 progenitors did not express p19 Arf , but it was induced in these cells following oncogene expression. Based on these observations, we propose that the high levels of apoptosis in BCR-ABL-expressing B-2 progenitors result from their relative sensitivity to p19 Arf . Additionally, it is likely that the increased proliferative potential of B-1 progenitors, which distinguishes them from B-2 progenitors, further contributes to the increased number of cells harvested from the cultures initiated with the former cells. Taken together, these results highlight distinctions in how these two B cell progenitor populations respond to oncogene expression.
These observations allow us to propose a model for what occurs when BCR-ABL is expressed in B-1 progenitors in vivo. Because of their high proliferative potential and relative resistance to oncogeneinduced death, a significant cohort of oncogene-expressing B-1 progenitors poised to generate ALL would build in the individual. These cells may in turn be exposed to microenvironmental factors that further promote their survival and/or expansion. For example, even though IL-7 and TSLP responsiveness are not required for the development of B-1 progenitor ALL, the differential responsiveness of B-1 progenitors to these cytokines could still be a factor in the proliferation and/or survival of BCR-ABL-expressing cells. The presence of a high number of BCR-ABL-expressing B-1 progenitors may in turn increase the probability that these cells cross the threshold from BCR-ABL expression to ALL initiation. In contrast, the lower resistance B-2 progenitors to oncogenic stress would result in a smaller pool of oncogene-expressing cells in the individual. In some cases, all oncogene-expressing B-2 progenitors may be eliminated, which would explain why some recipients of BCR-ABL-transduced B-2 progenitors never developed leukemia. We cannot exclude the additional possibility that oncogene-expressing B-1 progenitors are more prone to acquire key secondary mutations that further drive disease (17) , but more extensive genetic profiling will be necessary to assess this possibility.
The results in this study, which provide a developmental view of the origins of B-ALL, suggest that some aggressive forms of the disease may be malignancies of B-1 progenitors. This view allows clinical observations to be viewed from a new perspective. For example, one study stratified pediatric with Philadelphia + chromosome B-ALL patients into three groups based on leukocyte counts at the time of diagnosis and response to chemotherapy. The estimates of 5-y disease-free survival for these patients ranged from 49% for those with the lowest leukocyte counts to only 20% for those with the highest number (15) . It is tempting to speculate based on the present data that B-1 progenitors were transformed in the patients with the highest lymphocyte counts. B-1 B cells have been described in nonhuman primates (32) and humans (33) . It will be interesting, once human B-1 progenitors are resolved, to determine whether their response to oncogene expression differs from that of B-2 progenitors. 
